Efficacy and safety of eslicarbazepine acetate versus controlled-release carbamazepine monotherapy in newly diagnosed epilepsy: A phase III double-blind, randomized, parallel-group, multicenter study-Reference-Cited by-同舟云学术

Efficacy and safety of eslicarbazepine acetate versus controlled-release carbamazepine monotherapy in newly diagnosed epilepsy: A phase III double-blind, randomized, parallel-group, multicenter study

Published:2018-01-25 Issue:2 Volume:59 Page:479-491
ISSN:0013-9580
Container-title:Epilepsia
language:en
Short-container-title:Epilepsia

Author:

Trinka Eugen¹²³,Ben-Menachem Elinor⁴,Kowacs Pedro A.⁵,Elger Christian⁶,Keller Birgit⁷,Löffler Kurt⁷,Rocha José Francisco⁸,Soares-da-Silva Patrício⁸⁹¹⁰

Affiliation:

1. Department of Neurology; Christian Doppler Medical Center; Paracelsus Medical University Salzburg; Salzburg Austria

2. Center for Cognitive Neuroscience; Salzburg Austria

3. Department of Public Health and Health Technology Assessment; University for Health Sciences, Medical Informatics, and Technology; Hall in Tirol Austria

4. Institute for Clinical Neuroscience and Physiology; Sahlgrenska Academy; University of Gothenburg; Gothenburg Sweden

5. Neurological Institute of Curitiba; Curitiba Brazil

6. Department of Epileptology; University of Bonn; Bonn Germany

7. Accovion/Clinipace Worldwide; Eschborn Germany

8. Department of Research and Development; BIAL-Portela & C S.A.; S. Mamede do Coronado Portugal

9. Pharmacology and Therapeutics Unit, Department of Biomedicine; Faculty of Medicine; University of Porto; Porto Portugal

10. MedInUP; Center for Drug Discovery and Innovative Medicines; University of Porto; Porto Portugal

Funder

BIAL-Portela & Ca

Publisher

Wiley

Subject